Upper extremity deep vein thrombosis following a humeral fracture: a case report and literature review  by Chuter, Graham S.J. & Weir, David J.
Injury Extra (2005) 36, 249—252
www.elsevier.com/locate/inextCASE REPORT
Upper extremity deep vein thrombosis
following a humeral fracture: a case
report and literature review
Graham S.J. Chuter *, David J. WeirDepartment of Orthopaedics and Trauma, Newcastle General Hospital, Westgate Road,
Newcastle upon Tyne, NE4 6BE, UK
Accepted 30 October 2004Case report
A 72-year-old female accidentally fell while on holi-
day in Madeira sustaining an undisplaced simple
fracture to the surgical neck of her left humerus.
She attended the local clinic where her shoulder was
strapped tightly and immobilized by the local med-
ical team to protect it for her journey home.
On arrival back in the UK she attended the hos-
pital fracture clinic where non-operative manage-
ment was continued but the tight strapping was
changed to a collar and cuff sling.
Five days later, she was referred to A + E by her
GP with symptoms of pain and swelling in her left
antecubital fossa. On examination, she had bruising
at the level of the fracture and swelling at the
elbow, mostly anteriorly. Elbow flexion and exten-
sion were also limited. She had palpable thrombosis
in her superficial left forearm veins. An urgent
ultrasound scan was requested, which confirmed
thrombus in the superficial and deep venous systems
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doi:10.1016/j.injury.2004.10.036She was admitted to the ward and commenced on
treatment-dose low molecular weight heparin while
being warfarinised. The hospital haematologists
recommended warfarin treatment for 6 months.
After 3 months, her fracture had united with
almost full recovery of shoulder function following
physiotherapy.Literature review
Introduction
Upper extremity deep vein thrombosis (UEDVT) is an
increasingly important clinical entity with potential
for considerable mortality. Once considered rare,
UEDVT has become more common over the past few
decades while forearm DVT remains rare.10 This is
directly related to the increased use of central
venous catheters7 and comprises about 2% of all
deep venous limb thromboses.11
Although many risk factors for UEDVT have been
identified in the literature, bony trauma has not
been mentioned but has been recognised as a trig-
gering factor for lower extremity DVT for several
years.13
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Table 1 Advantages and disadvantages of UEDVT imaging modalities
Test Advantages Disadvantages
Ultrasound Inexpensive Poor detection of central thrombus
Non-invasive Clavicular acoustic shadowing
Reproducible
Contrast venography Inexpensive Contrast sensitivity
Good anatomy Phlebitis worsening thrombus
Assessment of treatments Contraindicated in pregnancy
Contrast CT Central thrombus detection Contrast (as above)
May detect extrinsic compression Contraindicated in pregnancy
Magnetic resonance Accurate detection Expensive
Excellent anatomy, including
collaterals and flow
Limited availability
Patient exclusion, e.g.:
 claustrophobia
 metallic implantsHumeral fractures are common, particularly in
the osteoporotic or elderly patient. They can cause
significant disability and carry a relatively high rate
of non-union (5—10%).
UEDVT is most commonly found in the axillary or
subclavian veins. It can be classified as primary or
secondary on the basis of pathogenesis.
Primary UEDVT is a rare disorder (2 per 100,000
persons per year) and refers to either effort-induced
thrombosis (Paget-Schroetter syndrome3) or idio-
pathic origin. In one study, however, 25% of patients
presenting with ‘‘idiopathic’’ UEDVTwere diagnosed
with cancer–—most commonly lung cancer or lym-
phomas–—within 1 year of follow-up.5 Asmany as 20%
of patients present with apparently spontaneous
episodes and the prevalence of inherited coagula-
tion disorders in patients with this disease ranges
from 10 to 26%.17
Secondary thrombosis accounts for most cases of
UEDVTand develops in patients with central venous
catheters, pacemakers or cancer. Other risk factors
include concomitant or previous lower limb DVT,6,12
hypercoagulable states including pregnancy and
contraceptive use,9 thoracic outlet syndrome14
and anatomic anomalies,4 and systemic illnesses
such as renal failure. Thus UEDVT typically occurs
in patients with a systemic illness who have a central
venous catheter.12
UEDVT is often completely asymptomatic in pre-
sentation, highlighting the need for awareness in the
critically ill patient. More often, though, patients
complain of vague neck or shoulder discomfort, arm
swelling, discolouration or pain. Obstruction of the
superior vena cava can cause facial oedema, blurred
vision, vertigo, or dyspnoea.15 Examination may
reveal a low-grade fever, sinus tachycardia (if venous
return to the heart is reduced as in SVC syndrome),mild cyanosis of the involved extremity, a tender
cord, arm or hand oedema, supraclavicular fullness,
or venous distension (jugular, chest, or distal). If a
central venous catheter is present, one ormore ports
may be occluded.
Although clinically suspicious, less than 50% of
these symptomatic patients will have imaging evi-
dence of UEDVT.7 Likewise, up to 50% of DVTs are
asymptomatic. It is, therefore, essential to have
evidence of UEDVT by diagnostic imaging before
anticoagulation. Blood tests (e.g. ‘D-dimers’–—a
measure of clot breakdown products) can be helpful
if negative but a positive result still requires con-
clusive imaging.
Ultrasound scanning is the initial diagnostic test
of choice but others include contrast venography,
contrast CT scanning, and magnetic resonance
angiography. These are compared in Table 1.
Treatment
Treatment begins symptomatically with elevation
and analgesia. Compression garments are a matter
of controversy. Anticoagulation is the cornerstone of
therapy and typically begins with ‘high dose’ unfrac-
tionated or low molecular weight heparin (LMWH)
administered sub-cutaneously while oral warfarin is
commenced. The heparin is discontinued when the
warfarin reaches a therapeutic level–—typically an
INR of 2.5 in first-event deep vein thrombosis. It is
recommended that warfarin be continued for a
minimum of 6 weeks in post-operative calf DVT
without other persistent risk factors. This increases
to 3 months in non-surgical patients and 6 months in
those with proximal vein thrombosis or pulmonary
embolus.8
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Pulmonary embolus complicates UEDVT in up to 36%
of patients and may be the presenting feature.17
Venous catheter removal is also a risk factor as
fibrinous coatings may break loose and embolise.
Post-thrombotic syndrome is caused by venous
hypertension secondary to outflow obstruction and
valvular injury. Symptoms vary from mild to severe
oedema with chronic pain, and skin ulceration of the
limb. It may occur in over half of patients and can
present up to 10 years later. Its incidence may be
reduced by the use of elastic compression stockings
in the initial period.2
Recurrence usually occurs in those with under-
lying medical problems or secondary UEDVT. Hence,
the short-term mortality rates are very high com-
pared with patients who have DVT7 of the lower
extremity.
Other complications include infection, SVC
obstruction, thoracic duct obstruction, and loss of
venous access. The latter is of great significance in
critical care for the administration of nutrition and
medication as well as patient monitoring.
Prevention
Primary UEDVT is difficult to predict. Screening
for thoracic outlet obstruction or coagulation dis-
orders has never been shown to be cost-effective.
Long-term anti-coagulant prophylaxis is normally
reserved for the prevention of secondary UEDVT
in high-risk patients.
Monreal et al.16 have shown that once-daily
subcutaneous administration of LMWH in cancer
patients with central venous catheters greatly
reduces the frequency of UEDVT, ensuring that
the first dose is given 2 h prior to catheterisation.
This has fewer bleeding complications, even in those
with poor nutrition or liver disease, than the pre-
viously suggested ‘mini-dose’ (1 mg) of warfarin.
Discussion
This patient had a secondary UEDVT caused by the
precipitating factors of trauma, tight strapping and
possibly air travel.
We have already discussed trauma as a known
cause of lower limb DVT, but in the literature,
humeral fracture is not a recognised risk factor
for UEDVT.
There is no published evidence that quotes tight
strapping as a cause for DVT but we know that
compression or obstruction of the venous drainage
of the upper limb can lead to venous stasis and
hence thrombosis.7,9,14Air travel is a known risk factor for lower limb DVT
but only a flight time of more than 3 h is quoted as
significant.1 One small study has looked at the
association with UEDVT but this was inconclusive.18
Other than the patient’s age (72) we could find no
other obvious risk factors.
In summary, there were many factors that may
have contributed to this lady’s UEDVT but we pro-
pose that it might not have occurred if the arm had
not been tightly strapped. We also recommend that
humeral fracture is added to the list of risk factors
for UEDVT in the same way that lower limb fractures
are well known to cause lower extremity DVT.
Learning points
Avoid tight strapping of injured limbs for sustained
periods.
Have a low index of suspicion for UEDVT in critically
ill patients or those with venous catheters and have
a low threshold for imaging.
Consider the use of LMWH in patients with long-term
venous catheters, particularly in the presence of
malignancy.
Consider UEDVT in the presence of underlying injury.References
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